Obesity drugmakers Orexigen, Vivus continue to falter

Bad news for struggling obesity drugmakers: Things aren't going to get any better, one analyst says. And the way he sees it, for leaders Orexigen ($OREX) and Vivus ($VVUS), they're likely to get much worse. More from FiercePharmaMarketing

Suggested Articles

Last year at ESMO, AZ and Merck showed Lynparza topped its rivals at fending off prostate cancer. Now, Lynparza has helped patients live longer, too.

Merck and Eisai are trying to take their Keytruda-Lenvima combo into additional cancers, and new data provide a glimpse of where it might go next.

Bristol-Myers already has one Opdivo combo approved in kidney cancer, but it’s going for another—and new trial data could be just the ticket.